New Clinical Trial for Multiple Myeloma Patients to Evaluate Safety and Efficacy of SurVaxM Vaccine
An immune-based vaccine created by researchers at Buffalo, New…
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreWhile myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreAn immune-based vaccine created by researchers at Buffalo, New…
Iceni Pharmaceuticals, formerly known as Big DNA Ltd.,…
The International Myeloma Foundation (IMF), the largest organization…
Positive data for the Phase 1 trial of…
Amgen announced it will present new data on its cancer…
Spain-based PharmaMar announced the company will present data from…